Friday, April 10, 2026
Sun Pharma's $12B binding bid for Organon drives premarket surge
Sun Pharma's $12B binding bid for Organon drives ~20% premarket surge.
According to reports from the Economic Times (cited by Investing.com and others on April 10, 2026), India's Sun Pharmaceutical Industries completed three months of due diligence on Organon and is finalizing a financing package for a firm all-cash offer expected in the coming weeks. This follows earlier 2026 speculation of a roughly $10B deal that Sun had previously called "speculative." The news sent shares from a prior close near $6.91 (after an already strong ~18% gain on April 9) to around $8.28 in premarket trading. Organon did not immediately comment. The potential deal would represent Sun's largest-ever acquisition and significantly expand its women's health and biosimilars portfolio.
Zentalis Positive DENALI Part 2a interim data selects 400mg QD 5:2 as pivotal azenosertib dos
Positive DENALI Part 2a interim data selects 400mg QD 5:2 as pivotal azenosertib dose in Cyclin E1+ ovarian cancer.
The April 9 announcement reported a clearly differentiated objective response rate at the 400mg once-daily 5-on/2-off schedule versus 300mg, with comparable safety, roughly half the adverse-event discontinuation rate of prior data, and no treatment-related deaths. This de-risks the biomarker-driven program, enabling advancement in the potentially pivotal DENALI Phase 2 (topline expected by year-end 2026) and confirmatory ASPENOVA Phase 3 (initiation in Q2 2026), while supporting pre-commercial activities and pipeline expansion. Fast Track designation adds regulatory momentum. Follow-through buying and an analyst price target increase amplified gains into April 10. (Sources: company press release via GlobeNewswire, SEC filing, analyst notes.)